Rheumato (Mar 2024)

Treatment of Gout in Patients with CrCl ≤30 mL/min and/or on Hemodialysis: A Review

  • Fares Saliba,
  • Omar Mourad,
  • Jonathan Mina,
  • Fadi Haddadin,
  • Laurence Aoun,
  • Shaza Almardini,
  • Saif Abu-baker,
  • Koushik Sangaraju,
  • Gaetano Di Pietro,
  • Daniel Gaballa,
  • Suzanne El-sayegh

DOI
https://doi.org/10.3390/rheumato4010005
Journal volume & issue
Vol. 4, no. 1
pp. 49 – 62

Abstract

Read online

Gout is highly prevalent in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), owing to impaired uric acid excretion. However, treating gout in this population is challenging due to concerns about medication safety and efficacy with reduced kidney function. This review examines the evidence of various pharmacologic and non-pharmacologic approaches to managing gout in CKD/ESRD. For acute gout flares, there is insufficient evidence to guide optimal dosing of NSAIDs, colchicine, and corticosteroids in advanced CKD. The risks generally outweigh the benefits of NSAIDs and colchicine. Corticosteroids appear safer but require individual risk-benefit assessments. Interleukin-1 inhibitors show promise, but larger studies are needed. For long-term urate lowering, xanthine oxidase inhibitors like allopurinol and febuxostat are preferred over probenecid and other uricosurics. However, studies specifically evaluating urate-lowering therapies in CKD are scarce, resulting in conflicting expert guidelines. Starting with low allopurinol doses and gradual titration can mitigate the risks. Higher allopurinol doses may be needed to reach urate targets in some CKD patients. Febuxostat’s safety in advanced CKD remains debated. Optimal gout management in dialysis patients is also unclear, including when to continue urate-lowering therapy. Overall, gout is often suboptimally treated in CKD/ESRD, highlighting the need for more research to guide therapy in this population. Improving management can significantly reduce the burden of these comorbid diseases.

Keywords